News

Deal Announcements

EKR Therapeutics Receives $13 Million Third Round

Thursday, August 16, 2007 5:00:00 AM PDT | VentureDeal Staff
CEDAR KNOLLS, NJ -- Specialty pharmaceutical company EKR Therapeutics, Inc. announced that it has raised $13 million in series C venture capital investment.

EKR is focused on acquiring and developing proprietary products for acute care conditions, including oncology (cancer) supportive care therapeutics.

Investors in the round were led by Quaker BioVentures and included previous investors NewSpring Capital, ESP Equity Partners and Merrill Lynch Capital Healthcare Finance Group.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1